SS-31 Half-Life and Pharmacokinetics: What Studies Report

Answer first: what this literature set does and does not contain

SS-31 — also referred to in the published record as elamipretide — is a synthetic mitochondria-targeting tetrapeptide. Readers searching for "SS-31 half life" are usually looking for a single number. The honest summary of the verified papers reviewed on this page is that none of them reported a numerical plasma half-life, clearance rate or volume of distribution in any species. The papers in this set were mechanistic studies, animal disease models, narrative reviews and clinical trial reports — not dedicated pharmacokinetic (PK) studies.

That does not mean nothing is known about how the molecule behaves in a body. The literature summarised here described the structural features that govern how the peptide enters cells, where it accumulates once inside, which routes of administration were used in each model, and how slowly some downstream effects appeared relative to any plausible plasma exposure window. Those are all pharmacokinetically relevant observations, and they are set out below with their citations. Where a parameter was simply not measured in these papers, the page says so rather than estimating.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, and note that SS-31 in research-chemical form is not an approved medicine.

Structure first: why SS-31's chemistry shapes its distribution

A 2025 review of elamipretide's structure and mechanism described it as a small, water-soluble aromatic-cationic tetrapeptide whose alternating aromatic and basic residues allow it to cross cell membranes and concentrate in the inner mitochondrial membrane, where researchers reported it associates with cardiolipin (PMID 39940712). The same review noted that this uptake was described as not requiring a membrane potential, which distinguishes the peptide from many cationic mitochondrial probes that depend on an intact potential to accumulate.

This matters for any discussion of pharmacokinetics because the compartment that appears to matter most is subcellular rather than plasma. A 2020 proteomic study mapped the mitochondrial protein interaction landscape of SS-31 and reported that the peptide interacted with a set of mitochondrial proteins involved in oxidative phosphorylation and substrate metabolism, consistent with localisation to the inner membrane rather than diffuse cytosolic distribution (PMID 32554501). A 2024 genome-wide CRISPR screen went further and identified phospholipid scramblase 3 as a biological target of SS-31, again placing the relevant site of action inside the mitochondrion (PMID 38530359).

The practical consequence, as discussed in a 2025 review of elamipretide's mechanism and therapeutic effects, is that tissue and organelle concentration may diverge from circulating concentration, so a plasma half-life — had one been reported in these papers — would not by itself describe how long the peptide remained engaged with its target membrane (PMID 40294492).

Routes of administration as reported, by model

The table below summarises only what the cited papers stated about how the compound was delivered and in what system. It does not convert between species or suggest any human application.

Absorption

No absorption parameters — bioavailability, time to maximum concentration, or absorption rate constant — were reported in the papers reviewed here. What can be stated is that the clinical programme described in the trial and approval literature used subcutaneous injection rather than an oral route (PMID 38602181, PMID 41335372). Parenteral delivery of a short peptide is the conventional approach when oral absorption is poor, and reviews of elamipretide in heart failure likewise described parenteral administration in the trials they summarised (PMID 35037146). Preclinical papers in this set used systemic in vivo dosing or direct exposure in cell culture and did not characterise absorption.

Distribution

Distribution is the best-described aspect of SS-31 behaviour in this literature, but it was described at the tissue and organelle level rather than as a volume of distribution. Two independent lines of evidence — the interaction proteomics work (PMID 32554501) and the CRISPR-based target identification (PMID 38530359) — converged on the inner mitochondrial membrane as the site where the peptide accumulates and acts.

Regarding central nervous system exposure, the mouse lipopolysaccharide study reported that systemically administered SS-31 improved mitochondrial dysfunction together with synaptic and memory impairment, an outcome that implies the peptide or its effects reached brain tissue (PMID 31747905). A 2026 study in a post-cardiac-arrest brain injury model similarly reported effects on microglia within the brain (PMID 41136322). Neither paper measured brain-to-plasma concentration ratios, so these remain pharmacodynamic inferences about central exposure, not direct distribution measurements.

Metabolism and clearance

No paper in this verified set reported metabolic pathways, metabolite identification, renal or hepatic clearance, or excretion balance for SS-31. The 2024 CRISPR study was conducted in a kidney-disease research context and identified a mitochondrial target rather than a clearance mechanism (PMID 38530359). Anything stated elsewhere about degradation by peptidases, renal filtration or elimination half-life falls outside what these papers support, and this page does not extrapolate.

Why "half-life" may be the wrong question for this molecule

Several reviews in this set emphasised that elamipretide's observable effects developed over weeks to months of repeated administration rather than tracking a short circulating exposure. A 2022 review of elamipretide in Barth syndrome cardiomyopathy characterised the therapeutic pattern as a gradual rebuilding of mitochondrial capacity over an extended treatment period (PMID 34623544). The 168-week open-label extension of the TAZPOWER trial likewise reported outcomes assessed across more than three years of continued dosing (PMID 38602181).

Reviews of the mechanism offered an explanation: if the peptide stabilises cardiolipin-dependent structure in the inner mitochondrial membrane and improves the efficiency of the respiratory apparatus, then the downstream benefit depends on remodelling of mitochondrial function rather than on moment-to-moment occupancy (PMID 40294492, PMID 39940712). In that framing, a plasma half-life measured in hours would say little about the time course of the biology.

Formulation research that alters exposure

One 2025 study used SS-31 itself as a targeting element rather than as the therapeutic payload: researchers constructed an SS-31–ferrostatin-1 conjugate and reported that it alleviated ferroptosis in hypoxia/reoxygenation cardiomyocytes by delivering the payload to mitochondria (PMID 39848110). This is a distribution-engineering approach — the peptide's mitochondrial tropism was used to steer another molecule — and it illustrates how strongly the field associates SS-31 with subcellular targeting rather than with favourable systemic PK.

Human data: what exists and what is missing

Human exposure to elamipretide has been substantial in a clinical sense. A 2026 review documented the first regulatory approval of elamipretide, and the long-term TAZPOWER extension reported efficacy and safety data in patients with Barth syndrome over 168 weeks of open-label treatment (PMID 41335372, PMID 38602181). Reviews have also summarised the heart-failure trial programme (PMID 35037146).

What is missing from this verified set is a human pharmacokinetic profile in publishable numbers: no maximum concentration, no time to peak, no terminal half-life, no clearance, no accumulation ratio on repeated dosing. Any page quoting a precise half-life figure for SS-31 is drawing on sources outside the papers listed here, and the value should be traced to a primary PK publication before it is relied upon.

Tolerability in long-term human use: What Studies Report

The 168-week open-label extension of TAZPOWER reported long-term efficacy and safety outcomes in patients with Barth syndrome receiving subcutaneous elamipretide, and the authors presented adverse-event data across that extended period (PMID 38602181). The first-approval review summarised the regulatory assessment of the same programme (PMID 41335372). Because adverse-event tables are context- and population-specific, the full listings in those publications are the appropriate source rather than any summary here. Preclinical papers in this set were not designed as toxicology studies and did not characterise a safety profile.

How to read half-life claims about SS-31

• Check the species and route. A figure derived from a rodent intravenous study does not transfer to subcutaneous human dosing, and none of the papers here provided either figure.
• Check the compartment. Plasma, whole tissue and mitochondrial membrane concentrations are different measurements; this literature emphasised the mitochondrial compartment (PMID 32554501).
• Separate PK from PD. The trial and review literature described effects accumulating across months of dosing (PMID 34623544).
• Distinguish approved elamipretide from research-grade SS-31. Regulatory review applies to the approved product described in the approval literature (PMID 41335372), not to material sold for laboratory use.

References

• Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice (Journal of Neuroinflammation, 2019)
• Elamipretide: First Approval (Drugs, 2026)
• Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential (International Journal of Molecular Sciences, 2025)
• SS-31@Fer-1 Alleviates ferroptosis in hypoxia/reoxygenation cardiomyocytes via mitochondrial targeting (Biomedicine & Pharmacotherapy, 2025)
• Targeting mitochondrial dysfunction with elamipretide (Heart Failure Reviews, 2022)
• Mitochondrial protein interaction landscape of SS-31 (PNAS, 2020)
• Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects (Biomedicine & Pharmacotherapy, 2025)
• Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31 (JASN, 2024)
• SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization (Neurotherapeutics, 2026)
• Elamipretide for Barth syndrome cardiomyopathy: gradual rebuilding of a failed power grid (Heart Failure Reviews, 2022)
• Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER (Genetics in Medicine, 2024)
• SS-31 Targets NOS2 to Enhance Osteogenic Differentiation in Aged BMSCs by Restoring Mitochondrial Function (Organogenesis, 2025)